Immunome heads into the week with a striking split: the stock is up 15% in five days, but insiders are selling into every uptick while short sellers are holding their ground.
The insider activity tells the most urgent story this week. Multiple insiders distributed more than $8.6 million in shares over just a handful of trading days. The Lead Independent Director sold roughly 100,000 shares across July 6-7 for combined proceeds near $2.4 million. The Chief Medical Officer sold on July 2 across three separate transactions totalling around $1.2 million. Board-affiliated vehicle Research Bridge Partners also sold north of $4.3 million between June 30 and July 2. The 90-day net position, however, shows a net positive 497,000 shares and roughly $10.7 million in value — suggesting that much of this selling may be against earlier exercised options rather than a pure conviction exit. Still, the concentration of sells right into a 15% weekly surge is hard to ignore.
Short positioning adds another layer of friction to the bullish read. Bears are not covering at scale despite the rally — short interest is running near 19.9% of free float, barely changed on the week (up roughly 1.2%). That level is elevated by any measure, and the ORTEX short score of 75.8, while slightly easing from a peak of 77.6 a week ago, remains in territory that reflects sustained short-side conviction. Borrow conditions, though, offer no particular squeeze catalyst. Cost to borrow is modest at just 0.53% — well off the isolated June 29 spike to 0.86% — and availability is actually loosening, climbing to 222% of short interest from roughly 179% a week prior. There are more than 46 million shares available to lend against roughly 18 million shorted, so bears face no forced-cover pressure from the lending market.
Options positioning aligns with the bullish price action rather than with the elevated short base. The put/call ratio has dropped to 0.20, well below its 20-day average of 0.25 and sitting in the lower third of its 52-week range (0.06–0.94). That lean toward calls suggests options traders are positioned for continuation rather than hedging against a reversal — a contrast worth noting given that short sellers are emphatically not capitulating.
The Street backs the bulls on paper, with all ten covering analysts rating the stock a buy and a mean target near $35.77 against a close of $24.39 — implying roughly 47% upside to consensus. Recent analyst activity has been constructive: Barclays initiated coverage at Overweight with a $36 target in late May, Truist raised its target to $37 in the same week, and Leerink trimmed modestly to $33 from $37 in mid-May after the May earnings print. The bull case rests on the Phase 3 RINGSIDE varegacestat data and the early read on IM-1021. Bears point to pipeline concentration, pre-profitability financials, and competitive risk in oncology — a fair concern for a name still burning cash with a negative EV/EBITDA of -5.7x. Institutional holders are broadly constructive: T. Rowe Price (17% of shares), Fidelity (15%), and Wellington Management — which added nearly 3.8 million shares in its most recent filing — are the largest holders.
Earnings are scheduled for August 7. The three most recent post-earnings moves have all been negative on a five-day basis, ranging from -3.8% to -14.5%, even when the one-day reaction was initially positive. The next print will be the key test for whether the summer rally has priced in enough — or too much — clinical optimism.
See the live data behind this article on ORTEX.
Open IMNM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
